ASCO 2025 | DEKA-1: DK210 in EGFR-expressing advanced cancers
Alexander Spira, MD, PhD, FACP, FASCO, NEXT Oncology Virginia, Fairfax, VA, comments on dose escalation and early clinical findings from the Phase I DEKA-1 trial (NCT05704985) of DK210, a tumor-targeted IL-2 × IL-10 immunocytokine, in patients with EGFR-expressing advanced cancers. The agent demonstrated immune activation with limited regulatory T cell expansion and manageable safety across dose levels. Adverse events were mostly mild to moderate, with signs of cytokine-driven activity without dose-limiting toxicities. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
